This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 87.2 kDa. The protein migrates as 95-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human ACE2, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) was more than 85% and the molecular weight of this protein is around 180-230 kDa verified by SEC-MALS.
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H3) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) with a linear range of 2-20 ng/mL (QC tested).
Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) captured on Biotin CAP - Series S sensor Chip can bind SARS-CoV-2 S protein (R683A, R685A), His Tag (Cat. No. SPN-C52H4) with an affinity constant of 54.5 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Loaded Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) on SA Biosensor, can bind SARS-CoV-2 S protein (R683A, R685A), His Tag (Cat. No. SPN-C52H4) with an affinity constant of 42.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Authors: Pratik Adhikary, Sashi Kandel, et al.
Journal: Advanced Therapeutics. 2021
Authors: Dong J, Huang B, Wang B, et al.
Journal: Scientific reports 2021
Authors: Tang J, Ravichandran S, Lee Y, et al.
Journal: Nature communications 2021
Authors: Esparza, Thomas J et al.
Journal: Scientific reports 2020
Application: Binding Assay
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. BioRxiv preprint. doi: https://doi.org/10.1101/2020.06.17.157982
Authors: Tyler N Starr, Allison J Greaney , Sarah K Hilton, et al.
Journal: BioRxiv 2020
Application: Flow cytometry
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.